Log in to save to my catalogue

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8220996

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a randomized trial involving nearly 40,000 persons, vaccine efficacy was 66% against moderate to severe–critical Covid-19 and 85% against severe–critical Covi...

Alternative Titles

Full title

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8220996

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8220996

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2101544

How to access this item